4-year-old boy's death in gene therapy trial halts Pfizer's final-stage study for muscular dystrophy.
Pfizer paused a final-stage study of its experimental gene therapy for muscular dystrophy after the death of a 4-year-old boy who received the treatment. The boy suffered a cardiac arrest and was part of a mid-stage study that has concluded. Pfizer is focused on ensuring participant safety and investigating the child's death. The therapy aims to treat Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease.
May 07, 2024
8 Articles